| First Author | Allen IC | Year | 2012 |
| Journal | Immunity | Volume | 36 |
| Issue | 5 | Pages | 742-54 |
| PubMed ID | 22503542 | Mgi Jnum | J:187326 |
| Mgi Id | MGI:5436198 | Doi | 10.1016/j.immuni.2012.03.012 |
| Citation | Allen IC, et al. (2012) NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-kappaB signaling. Immunity 36(5):742-54 |
| abstractText | In vitro data suggest that a subgroup of NLR proteins, including NLRP12, inhibits the transcription factor NF-kappaB, although physiologic and disease-relevant evidence is largely missing. Dysregulated NF-kappaB activity is associated with colonic inflammation and cancer, and we found Nlrp12(-/-) mice were highly susceptible to colitis and colitis-associated colon cancer. Polyps isolated from Nlrp12(-/-) mice showed elevated noncanonical NF-kappaB activation and increased expression of target genes that were associated with cancer, including Cxcl13 and Cxcl12. NLRP12 negatively regulated ERK and AKT signaling pathways in affected tumor tissues. Both hematopoietic- and nonhematopoietic-derived NLRP12 contributed to inflammation, but the latter dominantly contributed to tumorigenesis. The noncanonical NF-kappaB pathway was regulated upon degradation of TRAF3 and activation of NIK. NLRP12 interacted with both NIK and TRAF3, and Nlrp12(-/-) cells have constitutively elevated NIK, p100 processing to p52 and reduced TRAF3. Thus, NLRP12 is a checkpoint of noncanonical NF-kappaB, inflammation, and tumorigenesis. |
